2025-11-06 - Analysis Report
Okay, here's a report on Eli Lilly and Co. (LLY) based on the data provided.

## Eli Lilly and Co. (LLY) Stock Analysis

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **LLY Cumulative Return:** 262.07%
*   **VOO Cumulative Return:** 99.52%
*   **Absolute Divergence:** 110.9
*   **Relative Divergence:** 51.2 (This means LLY's outperformance is currently positioned in the 51.2th percentile of its historical range relative to VOO.)

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO).  The large positive divergence suggests strong relative performance. However, the relative divergence of 51.2 indicates that the current outperformance is around the median relative to its historical range, suggesting it is not at an extreme high.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | 11.0%  | 76.1%  | -17.0%  | -0.0   | 75.6   |
| 2016-2018  | 39.0%  | 68.9%  | 24.0%   | -0.0   | 103.6  |
| 2017-2019  | 41.0%  | 68.9%  | 19.0%   | 0.4    | 117.6  |
| 2018-2020  | 34.0%  | 79.8%  | 10.0%   | 0.4    | 151.1  |
| 2019-2021  | 53.0%  | 79.8%  | 7.0%    | 0.5    | 247.2  |
| 2020-2022  | 64.0%  | 79.8%  | 65.0%   | 0.4    | 327.4  |
| 2021-2023  | 125.0% | 78.9%  | 124.0%  | 0.2    | 521.7  |
| 2022-2024  | 134.0% | 81.2%  | 113.0%  | 0.2    | 690.9  |
| 2023-2025  | 153.0% | 83.5%  | 89.0%   | 0.2    | 849.2  |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate has increased dramatically over the periods, indicating accelerating growth.
*   **MDD:** Maximum Drawdown is consistently high, implying significant volatility.
*   **Alpha:** Alpha is generally positive and strong, especially in recent periods, signifying LLY's ability to generate excess returns above the market.
*   **Beta:** Beta values are low, suggesting LLY has been less sensitive to market movements.
*   **Cap(B):** Market capitalization has increased substantially, showing the company's growth in value.

### 2. Recent Price Action

*   **Current Price:** 948.8
*   **Last Market Data:** Price: 948.887, Previous Close: 906.86, Change: 4.63%
*   **5-day Moving Average:** 873.244
*   **20-day Moving Average:** 833.8425
*   **60-day Moving Average:** 772.5155

**Analysis:** The current price is significantly above all moving averages, indicating strong upward momentum. The 4.63% price increase from the previous close confirms a recent surge, which could be a reaction to news or market sentiment.

### 3. Market Risk Indicator & Hybrid Signal

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 78.53 (Overbought)
*   **PPO:** 1.0681
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Delta (20-day Relative Divergence):** 1.3 (+): Short-term increase
*   **Expected Return:** 128.6% (Projected excess return over S&P 500 with long-term investment)

**Analysis:**

*   The high MRI suggests that the model sees the stock as a good investment based on risk factors.
*   The RSI indicates that the stock is currently overbought, which *could* suggest a potential pullback.
*   The PPO (Percentage Price Oscillator) confirms the upward trend.
*   The Hybrid Signal recommends full investment with a small monthly addition.
*   The positive change in relative divergence signals short-term upward momentum.
*   The significant price change (4.63%) indicates a notable event or shift in market sentiment.
*   The high expected return suggests substantial long-term growth potential compared to the S&P 500.

### 4. Recent News & Significant Events

*   **Trump to Announce Deal With Eli Lilly, Novo Nordisk on Weight Loss Drugs:** This is a potentially positive catalyst for LLY, if the "deal" is favorable.
*   **News concerning Novo Nordisk (NVO):** While not directly about LLY, news about competitors in the weight loss drug market *can* influence LLY's stock, particularly regarding pricing and market outlook. The negative news regarding Novo Nordisk could be indirectly beneficial to Eli Lilly, as it might reduce competitive pressure.
*   **Amgen's Positive Earnings:**  Positive news from another major pharmaceutical company reflects positively on the sector.

**Analysis:**  The news cycle highlights the significance of weight loss drugs for both LLY and its competitors. A deal announced by a prominent figure like Trump could have a significant impact.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.76)
*   **Target Price:** Average: 921.19, High: 1190.00, Low: 700.00

**Analysis:**  Analysts are generally bullish on LLY. The average target price is slightly *below* the current price, suggesting limited short-term upside based on analyst models.  However, the high target price indicates that some analysts see considerable potential.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-10-30 | 6.22 | 17.60 B$    |
| 2025-08-07 | 6.3  | 15.56 B$    |
| 2025-05-01 | 3.07 | 12.73 B$    |
| 2024-10-30 | 1.08 | 11.44 B$    |
| 2025-10-30 | 1.08 | 11.44 B$    |

**Analysis:**

*   Earnings per Share (EPS) has shown a significant increase compared to previous periods.
*   Revenue has consistently grown, reflecting strong demand for LLY's products.
*   The latest EPS and revenue figures indicate robust financial performance and growth momentum.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $15.56B   | 84.27%        |
| 2025-03-31 | $12.73B   | 82.53%        |
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-06-30 | $18.27B   | 30.98%    |
| 2025-03-31 | $15.76B   | 17.50%    |
| 2024-12-31 | $14.19B   | 31.07%    |
| 2024-09-30 | $14.24B   | 6.81%     |
| 2024-06-30 | $13.56B   | 21.88%    |

**Analysis:**

*   Revenue and Profit Margin: Revenue has been steadily increasing, and the profit margin is exceptionally high, indicating strong operational efficiency.
*   Equity and ROE: Equity has been growing, reflecting an increase in the companyâ€™s net assets. The Return on Equity (ROE) shows strong profitability relative to shareholders' equity, particularly in recent quarters.

### 7. Overall Summary and Recommendation

LLY has demonstrated outstanding performance, significantly outperforming the S&P 500. Recent price action, combined with strong earnings and revenue growth, underscores its positive momentum. The news cycle focusing on weight loss drugs, where LLY is a key player, is a relevant factor. Analyst consensus remains bullish.

**Key Positives:**

*   Strong historical and recent stock performance.
*   High growth rates in revenue, EPS, and market capitalization.
*   Positive MRI and Hybrid Signal.
*   Favorable analyst ratings.
*   High and growing profit margins and ROE.

**Potential Risks:**

*   Overbought RSI, indicating potential for short-term pullback.
*   News regarding competitors (like NVO) can impact sentiment.
*   Current price exceeds analysts' average target.

**Recommendation:**

Based on the data, LLY appears to be a strong investment. The long-term expected return is compelling. However, given the overbought RSI and the potential impact of external news, a strategic approach is recommended. Consider small monthly additions to your portfolio.
